Atlas Capital Advisors’s VanEck Biotech ETF BBH Stock Holding History
Bought
Maintained
Sold
Other funds holding BBH
MIM
CCA
BFG
Atlas Capital Advisors's BBH Position: Q2 2026 in Review
Atlas Capital Advisors sold out of VanEck Biotech ETF (BBH) in Q2 2026, closing a stake of 5,450 shares — an estimated $1.02M sold.
Atlas Capital Advisors first reported a position in BBH in Q1 2018 and held it in 30 quarters. The position peaked at $1.21M in Q2 2021. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.
- Atlas Capital Advisors reported no remaining VanEck Biotech ETF position as of Q2 2026 after selling out during the quarter.
- Atlas Capital Advisors sold 5,450 VanEck Biotech ETF shares in Q2 2026, an estimated $1.02M.
- Atlas Capital Advisors first reported a position in VanEck Biotech ETF in Q1 2018 and held it in 30 quarters.
- Atlas Capital Advisors's VanEck Biotech ETF position peaked at $1.21M in Q2 2021.
- 110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.